METHOD OF SURGICAL TREATMENT OF VASOMOTOR RHINITIS Russian patent published in 2009 - IPC A61N1/00 A61B17/00 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to otolaryngology and can be applied in treatment of vasomotor rhinitis. Essence of method lies in argon-plasma destruction of cavernous plexuses in lower layer of nasal turbinate mucosa without injuring ciliary epithelium and bone lamella of turbinate. Local terminal anesthesia is performed by placing on both sides of lower nasal turbinates tampon soaked with 5% trimecaine hydrochloride solution or 10% lidocaine hydrochloride solution with further tampon removal in 4-5 min. Infiltration anesthesia is performed by introduction of 1% lidocaine hydrochloride or 1% novocaine hydrochloride into each lower nasal turbinate. Anesthetic is first introduced into medial and posterior parts of lower nasal turbinate through sticking anesthesiologic needle into middle of turbinate surface, then anesthetic is introduced into anterior part of lower nasal turbinate through sticking anesthesiologic needle into anterior turbinate surface. On upper surface of lower nasal turbinates puncture is made - mucosa canal with submucosa to bone, starting from anterior end of turbinate and to its posterior end, without puncturing mucosa of posterior end outwards. Flexible tip of plasma-destructor is introduced into canal to posterior end of lower nasal turbinate, through it immediately defocused flow of ionised argon plasma is supplied and process of argon-plasma uniform destruction of cavernous plexuses of submucosal layer of lower nasal turbinate is performed in axial and radial directions. Plasma-destructor tip is gradually during 5-7 sec removed from canal, by moving defocused flow of ionised argon plasma from coagulated parts to bleeding or insufficiently coagulated tissue zones. When plasma-destructor tip is removed from canal, puncture place is welded and supply of ionised argon plasma flow is stopped, then process is repeated on second lower nasal turbinate.

EFFECT: application of claimed invention allows to achieve reduction of nasal resistance to jet of air breathed out by patient, reduce time necessary to achieve required rate of mucociliary transport, stabilise nasal breathing, increase degree of ciliary epithelium preservation, eliminate formation of areas of new hemorrhages.

3 cl, 3 ex